Alvotech stock
ALVONASDAQHealthcareISIN LU2458332611
43Score 43 out of 100, Weak
Price and trend
76 / 100
Price history
−17% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 24% below its 52-week high. Largest decline in 4 years: 83% (February 2024 to June 2026).
Chart figures for advanced users
- SMA 50$5.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.19
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.00
- The lowest closing price of the last twelve months.
- Resistance$6.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alvotech belongs to the Drug Manufacturers (Specialty & Generic) industry (Luxembourg) and, with a market value of $1.67B, is number 55 of 78 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $598.9M (up 2.1%) and adjusted earnings per share of −$0.01.
- MEQIRI Score 43 out of 100 (Weak): rank 493 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $1.40, with the price 251% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 54.5% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 70
Weaknesses
- Above fair valuePrice 251% above the fair value of $1.40.Valuation 16
- DilutionShare count up 41% since 2022.Capital allocation 25
- Loss-makingLoss of $179.59M over the last 12 months.Fundamentals 22
Its standout strengths are technical analysis and growth, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $0.93 and expensive above $2.80 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9%. At 10% the fair value would be $1.09, at 8% it would be $1.86.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 12.2% on the twelve months before. Revenue has grown strongly since 2019, at around 62% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 60%, operating 13%, net 5%. Last 12 months: net −37%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Mar 2027in 125 days
- Last reported
- 11 Nov 2026EPS reported −$0.03 (expected −$0.04)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 44.4% since 15 Oct 2026.
- Earnings per share
- −$0.01+44.4%
- Revenue
- $598.9M−4.1%
- Earnings per share
- $0.23+2.2%
- Revenue
- $742.7M−2.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +11.0%2026 guidance reaffirmed: revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million.
“Based on our current expectations for product supply as well as anticipated contributions from milestone revenue in the second quarter, we are reaffirming our 2026 guidance of $650 million to $700 million in total revenue and $180 million to $220 million in adjusted EBITDA.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 20 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alvotech
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Trulieve CannabisTRLV $2.17B48
- Dermapharm HoldingDMP.DE $2.13B68
- FagronFAGR.BR $1.99B70
- Eton PharmaceuticalsETON $1.97B69
- Faes FarmaFAE.MC $1.73B71
- SupernusSUPN $1.72B62
- ANI PharmaceuticalsANIP $1.63B61
- PolyPeptide GroupPPGN.SW $1.61B42
ETFs that hold Alvotech
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.21B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.01% | 0.17% | €5.24B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Show 2 more
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE All-World UCITS ETF (USD) AccumulatingVWCE | 0.00% | 0.14% | €79.59B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.